<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04177680</url>
  </required_header>
  <id_info>
    <org_study_id>MAT-002</org_study_id>
    <nct_id>NCT04177680</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia</brief_title>
  <acronym>ENHANCE-IT</acronym>
  <official_title>Pharmacodynamic Effects of a Free-fatty Acid Formulation of Omega-3 Pentaenoic Acid to ENHANCE Efficacy in Adults With Hypertriglyceridemia: The ENHANCE-IT Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matinas BioPharma Nanotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Matinas Biopharma, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MB Clinical Research and Consulting LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Matinas BioPharma Nanotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, crossover study to assess the pharmacodynamic effects of MAT-9001,&#xD;
      an omega-3 free fatty acid compared to Vascepa (icosapent ethyl) on triglycerides and other&#xD;
      lipoprotein lipids in men and women with elevated triglycerides.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 3, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in plasma triglycerides</measure>
    <time_frame>28 days</time_frame>
    <description>Percent change in plasma triglycerides from baseline to end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in plasma lipoproteins</measure>
    <time_frame>28 days</time_frame>
    <description>Percent change in plasma lipoproteins from baseline to end of treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Omega-3 pentaenoic acid (MAT9001)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2g MAT9001 capsules twice daily with meals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icosapent ethyl (Vascepa)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2g Vascepa capsules twice daily with meals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega 3 pentaenoic acid</intervention_name>
    <description>Encapsulated omega-3 pentaenoic acid</description>
    <arm_group_label>Omega-3 pentaenoic acid (MAT9001)</arm_group_label>
    <other_name>MAT9001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>icosapent ethyl</intervention_name>
    <description>Encapsulated omega-3 acid ethyl esters</description>
    <arm_group_label>Icosapent ethyl (Vascepa)</arm_group_label>
    <other_name>Vascepa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, ≥18 y of age&#xD;
&#xD;
          -  Judged to be in generally good health&#xD;
&#xD;
          -  Fasting triglycerides ≥150 mg/dL to ≤499 mg/dL during screening&#xD;
&#xD;
          -  Body mass index of ≥20.0 kg/m2&#xD;
&#xD;
          -  No clinically significant findings in a 12-lead ECG or physical examination&#xD;
&#xD;
          -  Willing and able to undergo the scheduled study procedures&#xD;
&#xD;
          -  Understands study procedures and signs forms documenting informed consent to&#xD;
             participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory test result of clinical significance&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Clinically significant gastrointestinal, endocrine, cardiovascular, renal, hepatic,&#xD;
             pulmonary, pancreatic, neurologic, or biliary disorder&#xD;
&#xD;
          -  History of human immunodeficiency virus, hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Used any medication intended to alter the lipid profile within 4 weeks of the first&#xD;
             qualification visit&#xD;
&#xD;
          -  Active systemic infection&#xD;
&#xD;
          -  A condition the Investigator believes would interfere subject ability to provide&#xD;
             informed consent and/or comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Maki</last_name>
    <role>Study Director</role>
    <affiliation>MB Clinical Research and Consulting</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Matinas Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matinas Investigational site</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matinas Investigational Site</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matinas Investigational Site</name>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <zip>60101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matinas Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matinas Investigational site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matinas Investigational site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matinas Investigational site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eicosapentaenoic acid ethyl ester</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

